ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,379,590 | -84.7% | 201,400 | -76.9% | 0.42% | -85.0% |
| Q2 2023 | $9,028,423 | +28.1% | 870,629 | -0.1% | 2.79% | -4.0% |
| Q1 2023 | $7,050,435 | +27.1% | 871,500 | +147.4% | 2.91% | +83.4% |
| Q4 2022 | $5,547,040 | -35.2% | 352,193 | -35.2% | 1.59% | -45.2% |
| Q3 2022 | $8,559,000 | +13.6% | 543,776 | +0.8% | 2.90% | +24.8% |
| Q2 2022 | $7,532,000 | +58.7% | 539,545 | +96.0% | 2.32% | +18.1% |
| Q1 2022 | $4,747,000 | +14.1% | 275,333 | -3.8% | 1.96% | +16.4% |
| Q4 2021 | $4,162,000 | +33.4% | 286,226 | +65.1% | 1.69% | -4.4% |
| Q3 2021 | $3,120,000 | -5.9% | 173,327 | -8.2% | 1.76% | +19.4% |
| Q2 2021 | $3,314,000 | -60.9% | 188,719 | -44.0% | 1.48% | -68.1% |
| Q1 2021 | $8,486,000 | – | 336,737 | – | 4.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |